Johannes Waldschmidt
Overview
Explore the profile of Johannes Waldschmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burkhard-Meier A, Grube M, Jurinovic V, Agaimy A, Albertsmeier M, Berclaz L, et al.
Eur J Surg Oncol
. 2024 Sep;
50(12):108619.
PMID: 39270516
Background: Local ablative therapies (LAT) are increasingly used in patients with metastatic soft tissue sarcoma (STS), yet evidence-based standards are lacking. This study aimed to assess the impact of LAT...
2.
Haertle L, Munawar U, Hernandez H, Arroyo-Barea A, Heckel T, Cuenca I, et al.
Hemasphere
. 2024 Jul;
8(7):e110.
PMID: 38993727
Multiple myeloma (MM) is a genetically heterogeneous disease and the management of relapses is one of the biggest clinical challenges. alterations are established high-risk markers and are included in the...
3.
Maas-Bauer K, Stell A, Yan K, de Vega E, Vinnakota J, Unger S, et al.
Nat Commun
. 2024 Jan;
15(1):446.
PMID: 38199985
Patients with corticosteroid-refractory acute graft-versus-host disease (aGVHD) have a low one-year survival rate. Identification and validation of novel targetable kinases in patients who experience corticosteroid-refractory-aGVHD may help improve outcomes. Kinase-specific...
4.
Munawar U, Zhou X, Prommersberger S, Nerreter S, Vogt C, Steinhardt M, et al.
Commun Biol
. 2023 Dec;
6(1):1299.
PMID: 38129580
The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine treatment algorithms,...
5.
Steinhardt M, Truger M, Bittrich M, Zhou X, Noderer J, Riedhammer C, et al.
Haematologica
. 2023 Oct;
109(3):979-981.
PMID: 37794827
No abstract available.
6.
Frank B, Ihorst G, Herget G, Schafer H, Neubauer J, Calba M, et al.
Ann Hematol
. 2022 Dec;
102(3):603-611.
PMID: 36464695
The established standard to ensure state-of-the-art cancer treatment is through multidisciplinary tumor boards (TBs), although resource- and time-intensive. In this validation study, the multiple myeloma (MM)-TB was reexamined, aiming to...
7.
Engelhardt M, Bringhen S, Moreau P, Wasch R, Waldschmidt J
Haematologica
. 2021 Apr;
106(10):2539-2541.
PMID: 33910336
No abstract available.
8.
Engelhardt M, Selder R, Pandurevic M, Moller M, Ihorst G, Waldschmidt J, et al.
Dtsch Med Wochenschr
. 2017 Feb;
142(9):e51-e60.
PMID: 28241373
The established standard to ensure State-of-the-art cancer treatment - as a prerequisite in the national cancer plan and for comprehensive cancer centers (CCCs) today - is through interdisciplinary tumor boards...
9.
Lorenz J, Waldschmidt J, Wider D, Follo M, Ihorst G, Chatterjee M, et al.
Br J Haematol
. 2015 Oct;
174(6):985-9.
PMID: 26491948
No abstract available.
10.
Engelhardt M, Ihorst G, Landgren O, Pantic M, Reinhardt H, Waldschmidt J, et al.
Haematologica
. 2015 Jul;
100(10):1340-9.
PMID: 26160877
Additional malignancies in multiple myeloma patients after first-line and maintenance treatment have been observed, questioning whether specific risks exist. Second primary malignancies have also gained attention since randomized data showed...